Wheeler Bio

Executive Summary

Wheeler Bio is a private biologics CDMO headquartered in Oklahoma City, specializing in accelerating the development of antibody-based therapeutics through its proprietary 'Modular CMC' platform. Founded in 2018, the company offers integrated chemistry, manufacturing, and controls services from discovery to cGMP clinical supply, targeting bispecifics and fusion proteins. By packaging complex CMC workflows into defined modules, Wheeler Bio aims to reduce risk and shorten timelines for biotech clients. Currently operating at Phase 3 readiness, the company is positioned to support mid-to-late-stage clinical programs and potentially benefit from the growing demand for outsourced biologics manufacturing. While specific financials and client names are undisclosed, its niche focus on modular services could drive partnerships with innovative biotechs lacking in-house capabilities.

Upcoming Catalysts (preview)

• Q4 2026Announcement of first cGMP manufacturing contract for a lead client70% success
• Q3 2026Partnership with a mid-size biotech for bispecific antibody program60% success